Spots Global Cancer Trial Database for untreated aml
Every month we try and update this database with for untreated aml cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| A Study of Selinexor in Combination With Azacitidine and Venetoclax (SAV Regimen) in Treatment Naïve Participants With Acute Myeloid Leukemia | NCT05736965 | AML, Adult | Selinexor Azacitidine Venetoclax | 18 Years - | Shanghai Tong Ren Hospital | |
| Study of ABT-199 (GDC-0199) in Combination With Azacitidine or Decitabine (Chemo Combo) in Subjects With Acute Myelogenous Leukemia (AML) | NCT02203773 | Acute Myelogeno... Myelogenous Leu... Treatment Naive... | Posaconazole ABT-199 Decitabine Azacitidine | 60 Years - | AbbVie | |
| Safety Study of AG-120 or AG-221 in Combination With Induction and Consolidation Therapy in Participants With Newly Diagnosed Acute Myeloid Leukemia (AML) With an IDH1 and/or IDH2 Mutation | NCT02632708 | Newly Diagnosed... Untreated AML AML Arising Fro... AML Arising Fro... AML Arising Aft... | AG-120 AG-221 cytarabine daunorubicin idarubicin mitoxantrone etoposide | 18 Years - | Servier | |
| Safety Study of AG-120 or AG-221 in Combination With Induction and Consolidation Therapy in Participants With Newly Diagnosed Acute Myeloid Leukemia (AML) With an IDH1 and/or IDH2 Mutation | NCT02632708 | Newly Diagnosed... Untreated AML AML Arising Fro... AML Arising Fro... AML Arising Aft... | AG-120 AG-221 cytarabine daunorubicin idarubicin mitoxantrone etoposide | 18 Years - | Servier | |
| A Study Evaluating Venetoclax in Combination With Low-Dose Cytarabine in Treatment-Naïve Participants With Acute Myelogenous Leukemia | NCT02287233 | Acute Myelogeno... AML | Venetoclax Cytarabine | 60 Years - | AbbVie | |
| Study to Assess Adverse Events and Change in Disease State of Oral Venetoclax in Combination With Subcutaneous (SC) Azacitidine in Newly Diagnosed Adult Participants With Acute Myeloid Leukemia (AML) Who Are Ineligible for Intensive Chemotherapy in China | NCT05144243 | Acute Myeloid L... | Venetoclax Azacitidine | 18 Years - | AbbVie | |
| A Study of Selinexor in Combination With Azacitidine and Venetoclax (SAV Regimen) in Treatment Naïve Participants With Acute Myeloid Leukemia | NCT05736965 | AML, Adult | Selinexor Azacitidine Venetoclax | 18 Years - | Shanghai Tong Ren Hospital | |
| Adaptive Treatment for Acute Myeloid Leukemia Based on D14 MRD Results | NCT05736978 | AML MRD | Azacitidine Venetoclax Selinexor | 18 Years - | Shanghai Tong Ren Hospital | |
| Study of Orally Administered AG-120 in Subjects With Advanced Hematologic Malignancies With an IDH1 Mutation | NCT02074839 | Relapsed or Ref... Untreated AML Other IDH1-muta... Myelodysplastic... | AG-120 | 18 Years - | Servier | |
| Study of AG-120 (Ivosidenib) vs. Placebo in Combination With Azacitidine in Participants With Previously Untreated Acute Myeloid Leukemia With an IDH1 Mutation | NCT03173248 | Newly Diagnosed... Untreated AML AML Arising Fro... Leukemia, Myelo... | AG-120 Placebo Azacitidine | 18 Years - | Servier | |
| Study to Assess Adverse Events and Change in Disease State of Oral Venetoclax in Combination With Subcutaneous (SC) Azacitidine in Newly Diagnosed Adult Participants With Acute Myeloid Leukemia (AML) Who Are Ineligible for Intensive Chemotherapy in China | NCT05144243 | Acute Myeloid L... | Venetoclax Azacitidine | 18 Years - | AbbVie |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
